This milestone follows a two-month-long pilot study at the Department of Ophthalmology of a public hospital that assesses the accuracy, usability and patient satisfaction of AVAT, and the AVAT is the result of several years of dedicated research and development work by the Department of Ophthalmology at the National University Hospital and Centre for Innovation and Precision Eye Health at the Yong Loo Lin School of Medicine, National University of Singapore.
This marks the first commercial deployment of AVAT in Singapore, and the group received Class A Medical Device Registration for AVAT from the Health Science Authority (HSA) Singapore in August 2023.
Eddie Chng, managing director and CEO, DLL, says: “We are truly honoured to be given the opportunity to deploy AVAT in Singapore. Due to the convenience and reduced manpower needs, self-administered kiosks are becoming common, ranging from supermarket self-checkout machines to home-based blood pressure monitoring devices.”
“We know that loss of eyesight is irreversible, so the widespread deployment of devices like AVAT in the community is key not only for early diagnosis and intervention, but also to alleviate the workload at tertiary hospitals facing severe manpower shortages,” concludes Chng.
See also: Cosmosteel’s CEO Ong resigns after 3HA Capital offer declared unconditional
Shares in Disa closed flat at 0.1 cents on Jan 20.
